All In MedTech

Device Trial Radar · NCT05161806

Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe

An Open-label, Single-arm, Multicenter Study in Patients With Neovascular Age-related Macular Degeneration to Evaluate the Safety of SOK583A1 (40 mg/mL), a Proposed Aflibercept Biosimilar Product, Provided in a Prefilled Syringe

Last checked: Nov 19, 2026Latest source record: Nov 18, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

30

Actual

Start

Mar 11, 2022

Primary completion

May 4, 2022

Study completion May 4, 2022

Sponsor

Lead sponsor
SandozNot on our public-company list
Sponsor type
Industry
First posted
Dec 17, 2021

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was an open-label, single arm, multicenter, Phase IIIb study in subjects with (wet) nAMD, eligible for IVT aflibercept treatment.

Conditions

  • Neovascular Age-related Macular Degeneration (nAMD)

Interventions

  • SOK583A1 (40 mg/mL)Drug

    SOK583A1 provided in a Prefilled Syringe (PFS), which includes 2 mg aflibercept in 0.05 mL for IVT administration

  • Prefilled Syringe (PFS)Device

    Prefilled Syringe (PFS)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Ocular Treatment Emergent Adverse EventsTime frame: throughout the study, approximately 31 days
  2. Number of Participants With Non-ocular Treatment Emergent Adverse EventsTime frame: throughout the study, approximately 31 days

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Sandoz Investigational Site

    Marietta, Georgia

  • Sandoz Investigational Site

    Oak Forest, Illinois

  • Sandoz Investigational Site

    Liverpool, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.